keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer, NSCLC, SCLC

keyword
https://www.readbyqxmd.com/read/28767671/potential-paraneoplastic-syndromes-and-selected-autoimmune-conditions-in-patients-with-non-small-cell-lung-cancer-and-small-cell-lung-cancer-a-population-based-cohort-study
#1
Montserrat Miret, Erzsébet Horváth-Puhó, Anouk Déruaz-Luyet, Henrik Toft Sørensen, Vera Ehrenstein
BACKGROUND: Little is known about the occurrence and distribution of types of paraneoplastic syndromes (PNS) in patients with lung cancer. Identification of autoimmune PNS is particularly important for discerning them from immune-related adverse events of novel immunotherapies. We estimated the occurrence of PNS among patients with lung cancer and compared it with that in the general population. METHODS: In this registry-based cohort study in Denmark, we identified all patients with incident primary lung cancer between 1997 and 2010, and in a general-population comparison cohort matched on calendar time, sex, age, and residence...
2017: PloS One
https://www.readbyqxmd.com/read/28739724/therapeutic-role-of-mir-140-5p-for-the-treatment-of-non-small-cell-lung-cancer
#2
Valentina Flamini, Wen G Jiang, Yuxin Cui
BACKGROUND/AIM: Lung cancer is the second most common cancer in both men and women, after prostate and breast cancer, respectively. There are two main types of primary lung cancer, non-small cell lung cancer (NSCLC), which accounts for approximately 85-90% of all lung cancer cases, and small cell lung cancer (SCLC), which accounts for the other 10-15% of lung cancers. MiRNAs are small molecules that post-transcriptionally regulate many genes and contribute to many disease aetiologies, including tumours...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28720459/investigating-the-role-of-human-papillomavirus-in-lung-cancer
#3
E Argyri, E Tsimplaki, C Marketos, G Politis, E Panotopoulou
Lung cancer is the leading cancer worldwide among men and women with morbidity reaching 1.6 million. Human Papillomavirus is the causal factor of cervical cancer while its association with others is still under investigation. The purpose of our study is to examine the presence of HPV DNA as well as high-risk E6/E7 mRNA in patients with lung cancer. Lung tissues were collected during bronchoscopy and tested for HPV DNA and E6/E7 mRNA. 67 lung tissue samples were analysed. The age range was 49-85 years old (y...
June 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/28693444/the-value-of-ultrasound-guided-biopsy-of-fluorodeoxy-glucose-positron-emission-tomography-fdg-pet-positive-supraclavicular-lymph-nodes-in-patients-with-suspected-lung-cancer
#4
Lennart Werner, Franziska Aebersold Keller, Ujwal Bhure, Justus Egidius Roos, Katharina Tornquist, Maria Del Sol Pèrez-Lago, Oliver Gautschi, Klaus Strobel
BACKGROUND: Accurate lymph node staging is essential for adequate prognostication and therapy planning in patients with non-small cell lung cancer (NSCLC). FDG-PET/CT is a sensitive tool for the detection of metastases, including non-palpable supraclavicular lymph node (SCLN) metastases. Histological proof of metastatic spread and mutation analysis is crucial for optimal staging and therapy. The aim of this study was to investigate the value of ultrasound-guided fine needle aspiration cytology (FNAC) and core biopsy (CB) of FDG active, non-palpable SCLN's in patients with suspicion for lung cancer...
July 11, 2017: BMC Medical Imaging
https://www.readbyqxmd.com/read/28640869/development-of-an-automated-size-based-filtration-system-for-isolation-of-circulating-tumor-cells-in-lung-cancer-patients
#5
Satomi Yagi, Yasuhiro Koh, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Katsuya Endo, Seita Nakamura, Masayuki Higuchi, Hisashige Kanbara, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Circulating tumor cells (CTCs), defined as tumor cells circulating in the peripheral blood of patients with solid tumors, are relatively rare. Diagnosis using CTCs is expected to help in the decision-making for precision cancer medicine. We have developed an automated microcavity array (MCA) system to detect CTCs based on the differences in size and deformability between tumor cells and normal blood cells. Herein, we evaluated the system using blood samples from non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) patients...
2017: PloS One
https://www.readbyqxmd.com/read/28612596/prognostic-value-of-the-neutrophil-to-lymphocyte-ratio-nlr-in-lung-cancer-cases
#6
Berna Akinci Ozyurek, Tugce Sahin Ozdemirel, Sertac Buyukyaylaci Ozden, Yurdanur Erdogan, Bekir Kaplan, Tugba Kaplan
Haemogram assessment is a cheap and easy method which can be readily performed for almost all patients. Leucocyte, neutrophil and lymphocyte counts and the neutrophil to lymphocyte ratio (NLR) are markers of systemic inflammation. We here aimed to evaluate haemogram parameters of our patients with lung cancer according to the pathologic diagnosis of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Materials and Methods: The study included 386 patients diagnosed with lung cancer in our hospital between January 2006 and January 2014...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28607926/the-combination-of-the-tumor-markers-suggests-the-histological-diagnosis-of-lung-cancer
#7
Linjie Liu, Jinlong Teng, Lijun Zhang, Peishan Cong, Yuan Yao, Guirong Sun, Zhijun Liu, Teng Yu, Mingjun Liu
Tumor markers are beneficial for the diagnosis and therapy monitoring of lung cancer. However, the value of tumor markers in lung cancer histological diagnosis is unknown. In this study, we analyzed the serum levels of six tumor markers (CEA, CYFRA21-1, SCC, NSE, ProGRP, and CA125) in 2097 suspected patients with lung cancer and determined whether the combination of the tumor markers was useful for histological diagnosis of lung cancer. We found that CYFRA21-1 was the most sensitive marker in NSCLC. ProGRP showed a better clinical performance than that of NSE in discriminating between SCLC and NSCLC...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28588743/zar1-is-a-novel-epigenetically-inactivated-tumour-suppressor-in-lung-cancer
#8
Antje M Richter, Steffen Kiehl, Nicole Köger, Janina Breuer, Thorsten Stiewe, Reinhard H Dammann
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths with 1.8 million new cases each year and poor 5-year prognosis. Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby can promote cancer development and progression. RESULTS: In this study, we analysed ZAR1 (zygote arrest 1), which has been said to be a maternal-effect gene and its expression mostly limited to certain reproductive tissues. Our study shows that ZAR1 is expressed in normal lung but inactivated by promoter methylation in lung cancer...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/28572122/chemotherapy-for-pulmonary-large-cell-neuroendocrine-carcinomas-does-the-regimen-matter
#9
Jules L Derks, Robert Jan van Suylen, Erik Thunnissen, Michael A den Bakker, Harry J Groen, Egbert F Smit, Ronald A Damhuis, Esther C van den Broek, Ernst-Jan M Speel, Anne-Marie C Dingemans
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC.The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003-2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as "NSCLC-t", comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; "NSCLC-pt", with pemetrexed treatment only; and "SCLC-t", consisting of etoposide chemotherapy...
June 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28536345/viroimmunotherapy-of-thoracic-cancers
#10
REVIEW
Alexander S Dash, Manish R Patel
Thoracic cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and malignant pleural mesothelioma (MM), cause the highest rate of cancer mortality worldwide. Most of these deaths are as a result of NSCLC; however, prognoses for the other two diseases remain as some of the poorest of any cancers. Recent advances in immunotherapy, specifically immune checkpoint inhibitors, have begun to help a small population of patients with advanced lung cancer. People who respond to these immune therapies generally have a durable response and many see dramatic decreases in their disease...
January 4, 2017: Biomedicines
https://www.readbyqxmd.com/read/28535939/gene-expression-profiling-of-large-cell-lung-cancer-links-transcriptional-phenotypes-to-the-new-histological-who-2015-classification
#11
Anna Karlsson, Hans Brunnström, Patrick Micke, Srinivas Veerla, Johanna Mattsson, Linnea La Fleur, Johan Botling, Mats Jönsson, Christel Reuterswärd, Maria Planck, Johan Staaf
INTRODUCTION: Large cell lung cancer (LCLC) and large cell neuroendocrine carcinoma (LCNEC) constitute a small proportion of NSCLC. The WHO 2015 classification guidelines changed the definition of the debated histological subtype LCLC to be based on immunomarkers for adenocarcinoma and squamous cancer. We sought to determine whether these new guidelines also translate into the transcriptional landscape of lung cancer, and LCLC specifically. METHODS: Gene expression profiling was performed by using Illumina V4 HT12 microarrays (Illumina, San Diego, CA) on samples from 159 cases (comprising all histological subtypes, including 10 classified as LCLC WHO 2015 and 14 classified as LCNEC according to the WHO 2015 guidelines), with complimentary mutational and immunohistochemical data...
August 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28532540/-ocular-metastasis-in-lung-cancer-a-retrospective-analysis-in-a-single-chinese-hospital-and-literature-review
#12
REVIEW
Yan Xu, Yiduo Sun, Jing Zhao, Minjiang Chen, Lina Jiangde, Longyun Li, Wei Zhong, Mengzhao Wang
BACKGROUND: Eye is a rare site of lung cancer metastasis, and ocular metastasis is one of the largest challenges to cancer patients' quality of life (QOL). Here we present our experience on ocular metastasis of lung cancer and review relevant literature in an attempt to investigate the clinical features, treatment, and prognosis of these tumors. METHODS: The records of 9 patients with ocular metastasis of lung cancer treated at our hospital were analyzed. A literature review identified 42 cases reported in the last 10 years and their medical records were retrospectively estimated...
May 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28529640/lung-cancer-targeting-peptides-with-multi-subtype-indication-for-combinational-drug-delivery-and-molecular-imaging
#13
Yi-Hsuan Chi, Jong-Kai Hsiao, Ming-Huang Lin, Chen Chang, Chun-Hsin Lan, Han-Chung Wu
Lung cancer is the leading cause of cancer-related death worldwide. Most targeted drugs approved for lung cancer treatment are tyrosine kinase inhibitors (TKIs) directed against EGFR or ALK, and are used mainly for adenocarcinoma. At present, there is no effective or tailored targeting agent for large cell carcinoma (LCC) or small cell lung cancer (SCLC). Therefore, we aimed to identify targeting peptides with diagnostic and therapeutic utility that possess broad subtype specificity for SCLC and non-small cell lung cancer (NSCLC)...
2017: Theranostics
https://www.readbyqxmd.com/read/28521472/cd117-expression-is-a-predictive-marker-for-poor-prognosis-in-patients-with-non-small-cell-lung-cancer
#14
Tomohiko Sakabe, Junya Azumi, Tomohiro Haruki, Yoshihisa Umekita, Hiroshige Nakamura, Goshi Shiota
Non-small cell lung cancer (NSCLC) accounts for >85% of incidences of lung cancer, for which the predicted 5-year survival rates are low and recurrence rates remain high. Although it has been reported that the patients with SCLC cells that possess the cluster of differentiation (CD) 117 marker exhibited poor prognosis and poor response to chemotherapy, no studies concerning the association of CD117 expression with prognosis of the patients with NSCLC have been reported. An in vitro study reportedly revealed that CD117-positive cell populations in NSCLC cell lines exhibited cancer stem cell (CSC) phenotypes including self-renewal and chemoresistance...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28502129/diagnostic-role-of-rassf1a-and-p16ink4a-promoter-gene-hypermethylation-in-serum-dna-of-lung-cancer-patients-clinicopathological-significance
#15
Wafaa T El-Sherif, Sohair K Sayed, Sherif H Galal, Hoda A Makhlouf, Alaa T Hassan, Hosam A Yousef
The most common inactivation mechanism of tumor suppressor genes, RASSF1A and p16INK4a, in lung cancer is hypermethylation. We detected the methylation status of RASSF1A and p16INK4a in serum of lung cancer patients using methylation-specific PCR and analyzed their clinicopathological significance. Each of RASSF1A and p16INK4a hypermethylation was detected in 31.1% cancer patients but not in benign lung lesion patients. Hypermethylation was preferentially observed in small cell lung cancer (SCLC) for RASSF1A (50%), but not for p16INK4a...
June 2016: Egyptian Journal of Immunology
https://www.readbyqxmd.com/read/28482670/immune-checkpoint-inhibitors-in-lung-cancer-current-status-and-future-directions
#16
Yun Fan, Weimin Mao
Recently, the immune checkpoint inhibitors that target programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) have made a breakthrough in treating advanced non-small cell lung cancer (NSCLC) with the efficacy of approximately 20%; among which, nivolumab has acquired treatment indications in lung squamous cell carcinoma. The inhibitors targeting cytotoxic T lymphocyte associated antigen 4 (CTLA-4) are also undergoing clinical trials. Researches on immune checkpoint inhibitors have been rapidly implemented in a variety of different types of lung cancer, such as small cell lung cancer (SCLC) and locally advanced NSCLC, and these inhibitors began to be applied in combination with some established treatments, including chemotherapy, targeting therapy and radiotherapy...
April 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28447257/recent-developments-in-radiotherapy-for-small-cell-lung-cancer-a-review-by-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-society
#17
REVIEW
N Rodriguez de Dios, P Calvo, M Rico, M Martín, F Couñago, A Sotoca, B Taboada, A Rodríguez
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard treatment in patients with limited-stage disease is radiotherapy combined with chemotherapy. In extensive SCLC, the importance of consolidation thoracic radiotherapy in patients with a good treatment response has become increasingly recognized. In both limited and extensive disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer (NSCLC)...
April 26, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28432275/better-cancer-specific-survival-in-young-small-cell-lung-cancer-patients-especially-with-ajcc-stage-iii
#18
Haiyong Wang, Jingze Zhang, Fang Shi, Chenyue Zhang, Qinghua Jiao, Hui Zhu
It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age < 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged < 50, 3338 patients aged 50-59, 5937 patients aged 60-69, 4649 patients aged 70-79 and 1868 patients aged ≥ 80 between 2010 and 2013...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414324/correlation-between-histone-acetylation-and-expression-of-notch1-in-human-lung-carcinoma-and-its-possible-role-in-combined-small-cell-lung-carcinoma
#19
Wael Abdo Hassan, Shin-Ichiro Takebayashi, Mohamed Osama Ali Abdalla, Kosuke Fujino, Shinji Kudoh, Yamoto Motooka, Yonosuke Sato, Yoshiki Naito, Koichi Higaki, Joeji Wakimoto, Seiji Okada, Mituyoshi Nakao, Yuichi Ishikawa, Takaaki Ito
Combined small-cell lung carcinoma (cSCLC) is composed of small-cell lung carcinoma (SCLC) admixed with non-small-cell lung carcinoma (NSCLC). Evaluating the molecular differences between SCLC and NSCLC could lead to a better understanding of the pathogenesis of such neoplasms. Therefore, in this study, we investigated the correlation between histone acetylation and Notch1 expression in lung carcinoma. Using chromatin immunoprecipitation (ChIP) assay, we measured the level of acetylated histone H3 around the promoter region of Notch1 in SCLC and NSCLC cells...
August 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28410216/friend-leukemia-virus-integration-1-promotes-tumorigenesis-of-small-cell-lung-cancer-cells-by-activating-the-mir-17-92-pathway
#20
Lingyu Li, Wei Song, Xu Yan, Ailing Li, Xiaoying Zhang, Wei Li, Xue Wen, Lei Zhou, Dehai Yu, Ji-Fan Hu, Jiuwei Cui
Small cell lung cancer (SCLC) is regarded as the most devastative type of human lung malignancies. The rapid and disseminated growth pattern remains the primary cause of poor clinical prognosis in patients with SCLC. However, the molecular factors that drive rapid progression of SCLC remain unclear. Friend leukemia virus integration 1 (FLI1), an Ets transcription factor family member, has been previously reported to act as a major driver of hematological malignancies. In this study, we explored the potential role of FLI1 in SCLC...
June 27, 2017: Oncotarget
keyword
keyword
13192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"